Aurora Advances Global Medical Cannabis Portfolio with New Product Launches Across Key International Markets

Rhea-AI Summary

Aurora (NASDAQ: ACB) is expanding its global medical cannabis portfolio with scaled product launches across Canada, Germany, Poland, Australia and other regulated markets between now and June.

New formats include dried flower, pre-rolls and pastilles, with cultivar-specific potencies (THC up to 29%) and multi-compound pastilles. Aurora cites its GMP-certified manufacturing network to support reliable international supply.

Positive

• Multi-market rollout across Canada, Germany, Poland and Australia between now and June
• Format expansion into dried flower, pre-rolls and edible pastilles (precisely dosed)
• High-potency SKUs listed with THC up to 29% and specified cannabinoid profiles
• GMP-certified network supporting global manufacturing and supply consistency

Negative

• None.

News Market Reaction – ACB

-2.56%

-2.56% Session close to close

In the Apr 28 session, ACB declined 2.56%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement expands Aurora’s medical cannabis lineup with new high-THC dried flower and pre-ro...

Analysis

This announcement expands Aurora’s medical cannabis lineup with new high-THC dried flower and pre-rolls in Europe and Canada and precisely dosed pastilles in Australia, all supported by a GMP‑certified network. It builds on prior capacity additions aimed at international medical markets. Investors may track uptake of these SKUs, geographic sales mix, and how expanded formats contribute to sustaining medical revenue growth and margins highlighted in recent filings, particularly in key markets like Germany and Australia.

Key Figures

THC potency (Germany): 25–27% THC THC potency (Poland): 29% THC Black Raspberry pastilles dose: THC 20mg, CBD 20mg, CBN 30mg +5 more

8 metrics

THC potency (Germany) 25–27% THC San Raf Pink OG Kush dried flower for German medical market

THC potency (Poland) 29% THC Cannabis flos Aurora Chemango Kush dried flower in Poland

Black Raspberry pastilles dose THC 20mg, CBD 20mg, CBN 30mg Aurora Black Raspberry pastilles 60-pack in Australia

Blood Orange pastilles dose THC 32mg, CBD 32mg, CBG 32mg, CBC 10mg Aurora Blood Orange pastilles 60-pack in Australia

Pastille pack size 60-pack Pack size for Aurora medical pastilles in Australia

THC (Dank Matter) 24–30% THC WMMC Seasonal Stash Dank Matter 28g dried flower in Canada

THC (Custard Kush) 25–31% THC WMMC Seasonal Stash Custard Kush 28g dried flower in Canada

Daily price move 3.54% ACB price change in the last 24 hours before this news

Historical Context

5 past events · Latest: Apr 15 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 15	Strategic acquisition	Positive	+4.3%	Acquisition of Safari Flower Company to expand EU GMP medical capacity.
Mar 30	ESG recognition	Positive	-3.8%	Named to Women Lead Here list with 50% female executive leadership.
Feb 17	Conference participation	Positive	-1.4%	Participation in TD Cowen health care conference and investor meetings.
Feb 12	Market visibility	Positive	+5.7%	Nasdaq closing bell event emphasizing global medical cannabis strategy.
Feb 11	Portfolio expansion	Positive	-3.4%	Medical portfolio expansion in Australia and New Zealand using GMP facilities.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news often generated mixed price reactions, with several positive strategic updates followed by negative or muted next-day moves, and only some events aligning positively.

Recent Company History

Over the last six months, Aurora has emphasized its global medical cannabis strategy. On Feb 11, 2026, it expanded its portfolio in Australia and New Zealand, followed by a Nasdaq closing bell event on Feb 18 highlighting this focus. Participation in the TD Cowen health care conference and recognition for executive gender diversity underscored corporate positioning. Most recently, the Apr 15, 2026 Safari Flower acquisition expanded EU GMP capacity for key international medical markets, which aligns with today’s further portfolio expansion across Canada, Europe, and Australia.

Key Terms

gmp‑certified, cbd, cbg, cbc

4 terms

gmp‑certified regulatory

"reliable global supply through Aurora's extensive GMP‑certified network"

GMP‑certified means a manufacturer has been inspected and approved for following Good Manufacturing Practice, a set of government-backed rules that ensure products are made consistently, cleanly, and safely. Think of it as a restaurant passing a strict health inspection: it lowers the risk of defects, recalls, and regulatory shutdowns, so investors see it as a sign of reliable production, lower compliance risk, and steadier revenue potential.

cbd medical

"Pink OG KushTM | Indica, Dried Flower, THC 25-27%, CBD <1.0%"

Cannabidiol (CBD) is a natural compound found in hemp and cannabis plants that does not produce the “high” associated with THC. Investors care because CBD is sold in a wide range of consumer products and medical treatments, so changes in regulation, clinical evidence, or consumer demand can quickly affect company sales, margins and legal risk — think of it as a product line whose value depends on shifting rules and public trust.

cbg medical

"Blood Orange Pastilles | 60pck, THC 32mg, CBD 32mg, CBG 32mg"

CBG (cannabigerol) is a naturally occurring compound found in cannabis and hemp plants that does not cause a “high.” Think of it as a raw ingredient in a recipe: manufacturers and researchers can extract and test it for potential health or wellness uses. Investors care because demand, supply, research results, and regulatory decisions around CBG can affect product lines, sales growth, and the valuation of companies in the cannabis and health sectors.

cbc medical

"Blood Orange Pastilles | 60pck, THC 32mg, CBD 32mg, CBG 32mg, CBC 10mg"

A CBC, or complete blood count, is a routine medical test that measures key components of blood—red cells, white cells and platelets—much like a quick dashboard check of a car’s fluids and gauges. For investors, CBC results matter because they are used in clinical trials and safety monitoring to show whether a treatment affects basic health markers; abnormal changes can influence regulatory decisions, trial progress and a company’s risk profile.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

    NASDAQ | TSX: ACB

• Q1 launches reinforce Aurora's medical‑first strategy, expanding access to high‑quality products across multiple formats
• Scaled launches across Canada, Europe and Australia support growing demand in regulated international medical markets
• Continued focus on quality, patient needs and reliable global supply through Aurora's extensive GMP‑certified network

EDMONTON, AB, April 28, 2026 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian‑based leading global medical cannabis company, is significantly expanding its global medical cannabis portfolio, with new product launches rolling out across Canada, Europe and Australia. The company continues to shape the global cannabis landscape by introducing new products and formats around the world. The newly expanded lineup includes dried flower, pre‑rolls and pastilles, reflecting Aurora's long‑standing focus on innovation, quality and patient choice, while driving sustainable growth internationally.

"As our global medical business continues to grow, our focus remains on delivering consistency and reliability across the markets we serve," says Lana Culley, VP Innovation & International Operations at Aurora. "By expanding our offerings in key countries, we're responding to clear patient and prescriber demand with products that meet local regulatory standards, offer meaningful choice across formats, and can be supplied reliably at scale - all while reinforcing the level of quality and trust expected from us."

The new products align with Aurora's medical‑first strategy and leverage the company's global GMP‑certified manufacturing network.

Aurora's expanded medical cannabis offerings will roll out in their respective markets between now and June; new product launches include:

Germany – A broader portfolio of medical cannabis options

• San Raf^® – Pink OG Kush^TM | Indica, Dried Flower, THC 25-27%, CBD <1.0%. This cultivar has a spicy and sweet aroma profile of lemon, lavender, spice and is bred from OG Kush
• Daily Special^TM – Lemon Sorbet^TM | Sativa, Dried Flower, THC 21%, CBD <1.0%. This cultivar has an aroma profile of spice, wood, lemon and is bred from Gelonade X Biscotti

Poland – Expanded potency range across existing offerings

• Cannabis flos Aurora - Electric Honeydew^TM | Hybrid, Dried Flower, THC 27%, CBD ≤1.0%. This cultivar has an aroma profile of melon, gas, pine and is bred from Girl Scout Cookies x 91 OG Krypt Melon
• Cannabis flos Aurora – Chemango^TM Kush | Indica, Dried Flower, THC 29%, CBD ≤1.0%. This cultivar has an aroma profile of fruity, sour, chem and is bred from OG Kush x Wedding Cake x GMO x Fuel

Australia – Featuring pastilles, an edible format that is discreet, precisely dosed, and long-lasting

• Aurora^® – Black Raspberry Pastilles | 60pck, THC 20mg, CBD 20mg, CBN 30mg
• Aurora^® – Blood Orange Pastilles | 60pck, THC 32mg, CBD 32mg, CBG 32mg, CBC 10mg

Canada - Medical portfolio growth in core formats

• WMMC^TM - Seasonal Stash^TM Dank Matter^TM | Sativa, Dried Flower, 28g, THC 24-30%. This cultivar has an aroma profile of gas, licorice, vanilla, and is bred from Banana Puddintain x White Mac
• WMMC^TM - Seasonal Stash^TM Custard Kush^TM | Indica, Dried Flower, 28g, THC 25-31%. This cultivar has an aroma profile of creamy, berry, oak, and is bred from La Bomba x White Mac
• San Raf^® – Melon Mouth^TM | Hybrid, Pre-roll, 7x0.5g, THC 22-28%. This cultivar has an aroma profile of fruity, sweet, diesel and is bred from Girl Scout Cookies x Chem 91 x Crypt OG
• San Raf^® – Stink Biscuit^TM | Indica, Dried Flower, 3.5g, THC 22-28%. This cultivar has an aroma profile of gas, funk, sourdough and is bred from GMO x Animal Cookies

Together, these launches reflect Aurora's continued role in advancing regulated medical cannabis globally, supporting the growth of these markets with high‑quality products, diverse formats, and reliable supply.

About Aurora 

Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance, and a deep commitment to patient care. Aurora serves both medical and consumer markets across Canada, Europe, Australia, and New Zealand, with a strategic focus on high-margin opportunities and a medical-first approach. Aurora's portfolio of trusted, leading brands includes Aurora^®, MedReleaf^®, Pedanios^®, IndiMed™, San Raf^®, Tasty's^® and Whistler Medical Marijuana Co.^®. With world-class GMP-certified manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of Opening the World to Cannabis™.

Learn more at www.auroramj.com and follow us on X and LinkedIn. 

Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB". 

Forward Looking Information 

This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding new product launches across Aurora's key international markets, expectations for growing medical demand in regulated international markets, and the Company's continued focus on quality, patient needs and reliable global supply through Aurora's extensive GMP‑certified network.

These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, current and expected market trends, product supply and demand, financial performance, and ongoing global regulatory developments, as well as publicly available information from governmental sources, market research and industry, and assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the magnitude and duration of potential new or increased tariffs imposed on goods imported from Canada into the United States; the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations, management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 17, 2025 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-advances-global-medical-cannabis-portfolio-with-new-product-launches-across-key-international-markets-302754730.html

SOURCE Aurora Cannabis Inc.

FAQ

What new medical cannabis products did Aurora (ACB) announce for international markets in April 2026?

Aurora announced new dried flower, pre-rolls and pastilles launching across regulated markets through June. According to the company, launches include cultivar-specific dried flower (THC up to 29%) and multi-compound pastilles for Australia.

When will Aurora (ACB) roll out the new medical cannabis products in Europe and Australia?

Aurora plans rollouts between now and June 2026 in respective markets. According to the company, launches are scaled by country and timed to meet local regulatory requirements and supply needs.

What potency and formats are included in Aurora's (ACB) new product lineup?

The lineup includes dried flower, 0.5g pre-rolls and 60-count pastilles with specified cannabinoids. According to the company, THC potencies are listed up to 29% and pastilles show measured THC/CBD/CBN/CBG levels.

How does Aurora (ACB) ensure product quality and supply for its expanded medical portfolio?

Aurora cites its global GMP-certified manufacturing network to maintain consistency and reliability across markets. According to the company, the network supports scaled supply and adherence to local regulatory standards.

Will the new Aurora (ACB) pastilles be dosed consistently for medical patients?

Yes. Aurora states the pastilles are discreet and precisely dosed with quantified cannabinoid amounts. According to the company, Australian pastilles list specific mg levels for THC, CBD and other cannabinoids per 60-pack SKU.